Eleonora Teplinsky, MD, FASCO
@drteplinsky
Breast & gyn med onc @valleyhealthnj. Opinions my own. Host of INTERLUDE podcast. 📗 BEYOND THE PINK (2026). Patient education on Instagram.
What happens when you query chatGPT with 362 breast cancer cases? -46% responses differed from breast cancer expert opinion -when the same case was entered 3 times, the responses differed ~2/3 of the time ! -for examples, see 🧵..
New study evaluates the accuracy and reproducibility of #ChatGPT responses to #BreastCancer Tumor Board Patients. pubmed.ncbi.nlm.nih.gov/40466030/ ✍️@charlesbalchmd @nlinmd @hoperugo @DrWGradishar @KlimbergV @margenthalerj
Get your steps 👟 in!! New study from @TheLancet Public Health! ⬇️
Chance of a lifetime 🚨 to be #SocialMediaEditor for @gynoncjnls 👏 please consider applying!! 🌟 🎆 sciencedirect.com/journal/gyneco…
Ritu Salani from @UCLAHealth discusses new technologies that can help prevent ovarian cancer. Genetic testing, surveillance, and medications now play crucial roles in understanding cancer susceptibility, detecting it early, and reducing risk. Learn what steps you can take.
Congrats to all who earned FASCO distinction! You all are inspiring! @HemOncFellows
Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: brnw.ch/21wUiVu
Congratulations to all new FASCOs! So happy to see so many wonderful friends and inspiring colleagues recognized. Proud to be part of this community. #ASCO #FASCO #Oncology @ASCO @ASCOPres @umangtalking @TiansterZhang @apolo_andrea @drteplinsky @ErikaHamilton9 @jrgralow
Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: brnw.ch/21wUiVu
Congratulations @drteplinsky on your well deserved recognition 🎉!
#TumorBoardTuesday Anti-estrogen Tx is🗝️for the Tx of #breastcancer and progress continues on🔬of novel estrogen modifers 📢Join us Tuesday, 07-22-25 at 8PM ET as @YAbdouMD & @prarthnavb🗣️🎯ET resistance with next-gen SERDs in HR+ mBC RT and bring others into the discussion‼️
Excited to have earned FASCO designation!! @ASCO
Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: brnw.ch/21wUiVu
Proud of our work highlighting real world sexual health experiences of women with breast cancer. It’s a significant issue and many are not getting the treatment and information they need and deserve! #bcsm @LailaAgrawalMD
Women’s Insights on Sexual Health After #BreastCancer (WISH-BREAST) Survey. Authored by @LailaAgrawalMD, @drteplinsky, et al. #bcsm Read full article. brnw.ch/21wU813
Thank you @JCOOP_ASCO for highlighting our WISH-BREAST study on sexual health after breast cancer. 🙏 Please read the patient comments in this article. We need to take action and address this unmet need for cancer survivors. @drteplinsky
Women’s Insights on Sexual Health After #BreastCancer (WISH-BREAST) Survey. Authored by @LailaAgrawalMD, @drteplinsky, et al. #bcsm Read full article. brnw.ch/21wU813
🙋♀️Hello!! How's your schedule this fall? 🌟#WomenInOncology, save Sep 27-28 for #LEAD25! It's a fantastic opportunity for career development, networking with many inspiring and impactful women in oncology! 👉 bioascend.com/lead/ @JulieBrahmer @AnaVManana @KatieLaiMD_MPH…
After saying goodbye to anthracyclines— are we ready to also drop the carbo for our patients with stage II HER2+ breast cancer? Check out this discussion with friends and superstar breast oncs @YAbdouMD @JAMouabbi — powered by @OncLive
Sign up for free to read our exclusive June web feature! 🔐 This feature explores the evolution of the HER2-positive #BreastCancer landscape, including data from the phase 3 neoCARHP study and the phase 2 CompassHER2 pCR trial. @YAbdouMD @PTarantinoMD @JAMouabbi
You are incredible @ipreeshagul 🩷
SURREAL sharing my experience caring for others at the @MSKCME #oncologytoxicitysymposium Fun fact✔️My very first meeting @MSKCancerCenter as a college student I sat in the audience here , watching my mom’s oncologist speak. Being up here amongst these trailblazers is full ⭕️ 🥹
A nice patient friendly article on how metastases occur in breast cancer and how cells adapt to their metastatic environment. #bcsm knowablemagazine.org/content/articl…
#LEAD2025 is taking place on September 26-27 in Scottsdale, AZ! The goal of this conference is to empower women leaders in the #hematology and #oncology spaces by providing clinical updates, career development, and professional networking. Register today: loom.ly/jylJ7Gc
Exciting updates from #ASCO25 in today’s newsletter. • Breast cancer survivors open up about life after treatment • Tagrisso shows greater tumor shrinkage in EGFR+ lung cancer • Hopeful data for treating advanced HER2+ gastric cancer Read it all below.
Thank you for the opportunity to contribute to the Ed Book! A fantastic experience! #ASCO25
There really are no words for how grateful I am for this experience. Thank you to @ASCO and Ed Book staff Krystal and Meagan, to AEs @hoperugo and @PBarataMD, and to Don Dizon who mentored me in this role. And of course to our authors and readers who made Ed Book a success!
Want to share practice-changing research from #ASCO25 with your patients? 18 summaries highlighting key studies in #BreastCancer, #ColorectalCancer, #LungCancer, and more are available NOW: brnw.ch/21wT8gd